OTCMKTS:KHTRF Knight Therapeutics (KHTRF) Stock Price, News & Analysis $8.08 +0.01 (+0.12%) As of 11/19/2026 09:48 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Knight Therapeutics Stock (OTCMKTS:KHTRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Knight Therapeutics alerts:Sign Up Key Stats Today's Range$8.08▼$8.0850-Day Range$7.15▼$8.4652-Week Range$4.11▼$8.61Volume5,305 shsAverage Volume7,285 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Knight Therapeutics Inc. is a Canadian specialty pharmaceutical company that acquires, licenses and commercializes prescription medicines. Its portfolio includes products for a range of therapeutic areas, with a focus on bringing established and innovative treatments to markets where they may be underrepresented. Founded in 2014 and headquartered in Montreal, Knight serves Canada and selected international markets, including countries in Latin America and the Middle East and North Africa. It works through local subsidiaries, partners and licensing arrangements to register, distribute and market its products. Knight was founded by Jonathan Ross Goodman, who has served as its chief executive officer. The company’s business model centers on building its portfolio through product and business acquisitions, licensing agreements and commercial partnerships.AI Generated. May Contain Errors. Read More Receive KHTRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KHTRF Stock News HeadlinesNotice of Knight Therapeutics’ Third Quarter 2026 Results Conference CallOctober 29, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Approval of NIKTIMVO® in BrazilOctober 6, 2026 | financialpost.comFGet your evenings backThe Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes. No hours of flipping through charts, no second-guessing patterns. It's built for traders who want the result without the ritual: a short list and your evening back. Black Friday price is $7 versus the regular $247. One payment covers a full year, with no re-bills. | Profits Run (Ad)Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada’s Top Growing CompaniesSeptember 25, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | financialpost.comFKnight Therapeutics Announces Regulatory Submission of GEMTESA® in CanadaSeptember 15, 2026 | globenewswire.comKnight Therapeutics Inc KHTRFSeptember 10, 2026 | morningstar.comMKnight Therapeutics Announces Regulatory Approval of TAVALISSE® in ColombiaSeptember 1, 2026 | financialpost.comFSee More Headlines KHTRF Stock Analysis - Frequently Asked Questions How have KHTRF shares performed this year? Knight Therapeutics' stock was trading at $4.3765 at the beginning of 2026. Since then, KHTRF stock has increased by 84.6% and is now trading at $8.08. How do I buy shares of Knight Therapeutics? Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:KHTRF CIKN/A Webwww.knighttx.com Phone(514) 484-4483FaxN/AEmployees830Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:KHTRF) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.